Switching to Genentech’s Ocrevus (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to data from a Phase 3b clinical trial.
That finding, as well as data about patients’ adherence and persistence with Ocrevus, will be presented during MSVirtual2020, set for Sept. 11–13. MSVirtual2020 is a joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) online conference.
“While conditions of the nervous system are some of the most complex to understand and treat, we are committed to following the science to … slow and eventually stop disease progression in MS,” Levi Garraway, MD, PhD, said in a press release. Garraway is Genentech’s chief medical officer and head of Global Product Development.
Ocrevus is a second-generation anti-CD20 antibody, which targets B-cells, the immune cells that drive attacks against myelin in MS. It is approved for the treatment of primary progressive MS (PPMS) and relapsing MS.
An international Phase 3b clinical trial, CASTING (NCT02861014), was designed to evaluate Ocrevus’ safety and effectiveness in RRMS patients who showed suboptimal responses to other disease-modifying therapies (DMTs).
CASTING results will be presented through two posters: “Ocrelizumab Phase IIIb efficacy from CASTING: 2-year NEDA (MRI re-baselined) subgroup rates in RRMS patients with a suboptimal response to prior DMTs,” (abstract #P0219); and “Improvements in patient-reported SymptoMScreen scores among ocrelizumab-treated patients with RRMS: 2-year results from the CASTING clinical trial” (abstract #P1039).
The CASTING study involved 680 patients (435 women and 245 men) who had received one (60.4%) to two (39.6%) prior DMTs. Participants were enrolled due to the presence of disease activity related to brain lesions only (24.6%, assessed with MRI), relapses only (35.0%), and both (40.4%).
The trial’s main goal was to assess the proportion of participants achieving no evidence of disease activity (NEDA) — a status defined by the absence of new or enlarging brain lesions, relapses, and 24-week disability progression — after two years of treatment.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?